Loading...
XNAS
IRWD
Market cap128mUSD
Jun 10, Last price  
0.80USD
1D
35.64%
1Q
-48.38%
Jan 2017
-94.80%
IPO
-93.16%
Name

Ironwood Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
146.19
P/S
0.37
EPS
0.01
Div Yield, %
Shrs. gr., 5y
0.52%
Rev. gr., 5y
-3.89%
Revenues
351m
-20.63%
10,464,00022,216,00036,102,00043,857,00065,871,000150,245,00022,881,00076,436,000149,555,000273,957,000298,276,000346,639,000428,413,000389,523,000413,753,000410,596,000442,735,000351,410,000
Net income
880k
P
-52,752,000-53,874,000-71,185,000-52,981,000-64,852,000-72,624,000-272,812,000-189,618,000-142,669,000-81,708,000-116,937,000-282,368,000-15,314,000106,176,000528,448,000175,065,000-1,002,239,000880,000
CFO
104m
-43.55%
-6,759,000-28,195,000-3,998,000-67,899,000-75,237,000-69,633,000-273,355,000-155,568,000-106,927,000-25,433,000-99,563,000-70,882,00010,725,000168,836,000261,895,000273,763,000183,427,000103,549,000
Earnings
Aug 06, 2025

Profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
IPO date
Feb 03, 2010
Employees
219
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
351,410
-20.63%
442,735
7.83%
410,596
-0.76%
Cost of revenue
111,421
117,660
45,683
Unusual Expense (Income)
NOPBT
239,989
325,075
364,913
NOPBT Margin
68.29%
73.42%
88.87%
Operating Taxes
64,318
83,490
77,357
Tax Rate
26.80%
25.68%
21.20%
NOPAT
175,671
241,585
287,556
Net income
880
-100.09%
(1,002,239)
-672.50%
175,065
-66.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,357
(116,854)
BB yield
-0.36%
5.06%
Debt
Debt current
3,189
202,686
3,065
Long-term debt
239,089
530,521
432,514
Deferred revenue
Other long-term liabilities
(12,304)
28,415
9,766
Net debt
153,719
641,053
(235,698)
Cash flow
Cash from operating activities
103,549
183,427
273,763
CAPEX
(142)
(273)
(136)
Cash from investing activities
(142)
(1,026,318)
(136)
Cash from financing activities
(106,970)
277,160
(237,553)
FCF
188,609
276,725
271,590
Balance
Cash
88,559
92,154
656,203
Long term investments
15,074
Excess cash
70,988
70,017
650,747
Stockholders' equity
(1,696,652)
(1,701,490)
(696,222)
Invested Capital
2,011,903
2,099,148
1,773,625
ROIC
8.55%
12.48%
15.15%
ROCE
76.13%
81.75%
33.87%
EV
Common stock shares outstanding
160,084
155,435
186,312
Price
4.43
-61.28%
11.44
-7.67%
12.39
6.26%
Market cap
709,172
-60.12%
1,778,176
-22.97%
2,308,406
20.41%
EV
862,891
2,419,229
2,072,708
EBITDA
242,000
326,650
366,331
EV/EBITDA
3.57
7.41
5.66
Interest
33,034
21,629
7,598
Interest/NOPBT
13.76%
6.65%
2.08%